Can MRI biomarkers at 3 T identify low-risk ductal carcinoma in situ?

Clin Imaging. 2016 Jan-Feb;40(1):125-9. doi: 10.1016/j.clinimag.2015.07.026. Epub 2015 Jul 26.

Abstract

Objective: The objective was to explore whether 3-T magnetic resonance imaging (MRI) can identify low-risk ductal carcinoma in situ (DCIS).

Methods: Dynamic contrast-enhanced and diffusion-weighted (DWI) MRI features of 36 DCIS lesions [8 low risk, Van Nuys Pathologic Classification (VNPC) 1; 28 high risk, VNPC 2/3] were reviewed. An MRI model that best identified low-risk DCIS was determined using multivariate logistic regression.

Results: Low-risk DCIS exhibited different DWI properties [i.e., higher contrast-to-noise ratio (P=.02) and lower normalized apparent diffusion coefficients (P=.04)] than high-risk DCIS. A model combining these DWI features provided best performance (area under receiver operating characteristic curve =0.86).

Conclusions: DWI may help identify DCIS lesions requiring less therapy.

Keywords: Biomarker; Diffusion-weighted imaging; Ductal carcinoma in situ; MRI.

MeSH terms

  • Biomarkers
  • Breast Neoplasms / pathology*
  • Carcinoma, Intraductal, Noninfiltrating / pathology*
  • Contrast Media
  • Diagnosis, Differential
  • Diffusion Magnetic Resonance Imaging
  • Female
  • Humans
  • Image Enhancement
  • Logistic Models
  • Magnetic Resonance Imaging / methods*
  • Middle Aged
  • ROC Curve
  • Reproducibility of Results

Substances

  • Biomarkers
  • Contrast Media